Zetta Venture Partners is the first focused fund committed to delivering exceptional returns from the high-growth analytics market.  The firm, founded by industry veteran Mark Gorenberg, launched in 2013.  With offices in San Francisco and Utah, and a worldwide network of partners, entrepreneurs and investors, Zetta Venture Partners is at the forefront of the next huge and long-lasting investment opportunity.  Focused funds deliver exceptional returns. In fact, over the past 10 years, focused funds have outperformed all funds by 72 basis points, according to the National Venture Capital Association. As an analytics-only fund, Zetta delivers the expertise, network and portfolio to create ongoing, exceptional deal flow.

Zetta Venture Partners

delta v is MIT’s premier venture accelerator, that prepares entrepreneurs to hit escape velocity and launch into the real world. From June to early September, teams have dedicated space in the co-working environment of the Martin Trust Center for MIT Entrepreneurship on the MIT campus, or the NYC Startup Studio in Manhattan. They work on their ventures full-time for the whole summer. Teams define and refine their target market, conduct primary market research and build knowledge about their customers and users. They run experiments to validate or invalidate their key hypotheses with potential customers. They be building and nurturing their founding team. They make progress on the mechanics of starting their venture.

MIT delta v

Pillar VC partners with unstoppable founders from the moment of inception, providing the first capital. The firm is committed to helping founders grow with their companies, investing in their personal and professional development with connections, coaching, and community. From university spinouts led by first-time founders to serial entrepreneurs, backing the next generation of big, meaningful companies in Boston. Pillar VC is open to high-potential ventures of any type, with the bulk of our portfolio related to machine intelligence, AI, hardware, enterprise software, blockchain, quantum, digital health, and synthetic biology.

Pillar VC

Innospark Ventures is a new breed of early-stage venture capital firm, investing in the AI-driven economy.

Innospark Ventures

Spark Capital is an early-stage venture capital firm that invests in exceptional products and the creative individuals behind them. Known for embracing risk and a unique approach, Spark Capital has backed companies like Twitter, Discord, Anthropic, Cruise, Niantic, Oculus, Warby Parker, and Tumblr. Recognizing that there are no set playbooks or formulas for success, the firm supports founders in achieving success on their own terms. Spark Capital invests across all sectors and stages, operating out of San Francisco, Boston, and New York City.

Spark Capital

VideaHealth

VideaHealth is offers dentistAI’s software automatically detects pathologies in dental imaging, helping dentists avoid missing diseases and effectively communicating treatment recommendations to patients. Today, dentists miss up to 50% of pathologies in dental x-rays. Treatment delays or non-treatment often results in significant health risks for the patient and a loss of revenue for the dentists as he cannot treat missed diseases.

VideaHealth is a dental AI company that offers an AI-powered platform called VideaAI to assist dentists in identifying and communicating dental diseases and conditions. The platform utilizes FDA-cleared AI algorithms and machine learning models trained on a vast dataset of over 100 million data points from various sources, including dental service organizations (DSOs), insurance companies, and universities.

Competing in the Age of Artificial Intelligence: VideaHealth

VideaHealth’s Comprehensive Study Highlights Many Benefits of Dental AI

Dental AI Startup VideaHealth Nabs $20M to Expand AI-Based Diagnostics

VideaHealth Raises $20 Million to Expand AI in the Dentist’s Chair for Millions of Patients

How VideaHealth, Heartland Dental completed the largest dental AI rollout

VideaHealth Dental AI Solution Receives FDA 510(k) Clearance, Establishing Industry-wide Benchmark for Clinical Accuracy

Dental AI Revolutionizes Oral Health: VideaHealth Receives Landmark FDA Clearance

VideaHealth Announces Foundational Dental AI Patent Granted by U.S. Patent and Trademark Office (USPTO)

VideaHealth: The Dental AI Trusted by Dentists and DSOs

VideaHealth Artificial Intelligence Dental Assist Receives FDA Clearance

VideaHealth raises $20M for AI-enabled dental care

VideaHealth: This Company’s AI Helps Dental Clinicians Detect Signs Of Oral Disease

A Few Questions with Florian Hillen

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

VideaHealth is an AI-powered startup that offers solutions such as diagnostic tools, practice management, and claims analysis with a focus on dental care. In May 2022, the firm obtained 510 (k) FDA approval for its AI-powered cavity detection algorithm, Videa Caries Assist, which it claims is an industry first. The algorithm was built on the firm’s dataset with over 100 million data points gathered from dental service organizations (DSOs), insurance companies, clearinghouses, and universities.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

VideaHealth and vVARDIS Team Up, Elevating Preventative Dental Care for Millions

<div>
 
 VideaHealth is an AI-powered startup that offers solutions such as diagnostic tools, practice management, and claims analysis with a focus on dental care. In May 2022, the firm obtained 510 (k) FDA approval for its AI-powered cavity detection algorithm, Videa Caries Assist, which it claims is an industry first. The algorithm was built on the firm&rsquo;s dataset with over 100 million data points gathered from dental service organizations (DSOs), insurance companies, clearinghouses, and universities.&nbsp;
 
 
 Additionally,&nbsp; the firm developed an imaging analysis tool to identify and communicate dental diseases and other diseases using X-rays during a consultation. The AI-powered tool was available for investigative use only as of May 2022, and the company was pursuing regulatory clearance for clinical image processing. It operates a B2B model, partnering with dental support organizations and insurance providers across the US. In addition to its diagnostic tools, the firm provides actionable insights into dental practices to support practice management. It also offers an automatic claims review software for insurance providers to assess all incoming claims.&nbsp;
 
 
 Funding and financials
 
 
 In March 2022, the firm raised USD 20 million in a Series A funding round led by Spark Capital for the purpose of expanding its AI-based diagnostics solution to dentists. The firm has planned to expand its services to more than 6,750 practices by the end of 2023.
 
 
 
</div>

VideaHealth is an AI-powered startup that offers solutions such as diagnostic tools, practice management, and claims analysis with a focus on dental care. In May 2022, the firm obtained 510 (k) FDA approval for its AI-powered cavity detection algorithm, Videa Caries Assist, which it claims is an industry first. The algorithm was built on the firm’s dataset with over 100 million data points gathered from dental service organizations (DSOs), insurance companies, clearinghouses, and universities.Additionally, the firm developed an imaging analysis tool to identify and communicate dental diseases and other diseases using X-rays during a consultation. The AI-powered tool was available for investigative use only as of May 2022, and the company was pursuing regulatory clearance for clinical image processing. It operates a B2B model, partnering with dental support organizations and insurance providers across the US. In addition to its diagnostic tools, the firm provides actionable insights into dental practices to support practice management. It also offers an automatic claims review software for insurance providers to assess all incoming claims.Funding and financialsIn March 2022, the firm raised USD 20 million in a Series A funding round led by Spark Capital for the purpose of expanding its AI-based diagnostics solution to dentists. The firm has planned to expand its services to more than 6,750 practices by the end of 2023.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

VideaHealth is a dental AI company that offers an AI-powered platform called VideaAI to assist dentists in identifying and communicating dental diseases and conditions. The platform utilizes FDA-cleared AI algorithms and machine learning models trained on a vast dataset of over 100 million data points from various sources, including dental service organizations (DSOs), insurance companies, and universities.
VideaAI's core capabilities include detecting caries (cavities), measuring radiographic bone levels, identifying periapical radiolucencies, detecting calculus, and recognizing other dental abnormalities across all age groups, including pediatric patients. The platform seamlessly integrates into dentists' existing workflows, automatically analyzing X-ray images to provide real-time clinical decision support.
Through partnerships with industry leaders like Henry Schein One and DSOs such as Heartland Dental and 42 North Dental, VideaHealth aims to make AI-powered dentistry the standard of care. In a joint study with Heartland Dental, VideaHealth's AI platform helped clinicians detect more caries lesions and reduced errors, leading to faster, more accurate diagnoses and enabling better preventative care.
Key customers and partnerships
VideaHealth's AI technology is widely adopted by leading DSOs and dental practices across the US. Notable customers and partners include:
- Heartland Dental: A major DSO with over 1,700 supported dental practices across 38 states. VideaHealth completed the largest dental AI rollout in history by implementing its technology across Heartland Dental's network in less than 10 weeks.
- 42 North Dental: A DSO that has integrated VideaAI to elevate the level of care provided to patients and calibrate providers for consistent diagnoses and treatment planning.
- Henry Schein One: A joint venture with the world's largest dental service and software provider, enabling the integration of VideaHealth's AI into the widely used Dentrix and Dentrix Ascend practice management software platforms, reaching tens of thousands of dental practices.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

VideaHealth

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless